4 stories
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
The UK's medicines regulator is investigating whether clinics are breaking the law by making unsubstantiated medicinal claims for unregulated peptide therapies.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.